top of page


Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
13/10/2026 SAB BIO received US FDA Fast Track Designation for SAB-142 in stage 3 T1D Legacy Healthcare received US FDA Breakthrough Therapy Designation for CINAINU® (LH-8) in alopecia areata Evergreen Therapeutics received FDA Fast Track Designation for EG-501 in NPSLE-CI SAB BIO received US FDA Fast Track Designation for SAB-142 in stage 3 T1D (Ref) SAB Biotherapeutics’ SAB-142 received US FDA Fast Track Designation for treatment of new-onset Stage 3 Type 1 diabetes (T1D). T
decodeMR Team
Oct 151 min read


Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
07/04/2026 Climb Bio announced FDA Fast Track Designation for budoprutug for the treatment of pMN Climb Bio announced FDA Fast Track Designation for budoprutug for the treatment of pMN ( Ref ) Climb Bio announced that the US FDA had granted Fast Track Designation to budoprutug (anti-CD19 mAb) for the treatment of primary membranous nephropathy (pMN) Brudoprutug was being studied in Phase 2 patinets with pMN The company anticipated initial data from Phase 2 study in H2 2026
decodeMR Team
Apr 91 min read


Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
10/03/2026 Redx’s RXC008 granted US FDA fast track designation for fibrostenotic CD Redx’s RXC008 granted US FDA fast track designation for fibrostenotic CD ( Ref ) Redx Pharma announced that the US FDA had granted fast track designation to RXC008 (a GI-restricted pan-ROCK inhibitor) for the treatment of patients with fibrostenotic crohn’s disease (CD) Lisa Anson, CEO, Redx Pharma: “ Redx have been working closely with the FDA and the STAR consortium to define the regulatory
decodeMR Team
Mar 111 min read
bottom of page